Washington calls for temporary suspension of Johnson & Johnson vaccine

15

U.S. health agencies on Tuesday advised U.S. health officials to temporarily suspend the use of the single-dose Covid-19 vaccine produced by Johnson & Johnson. The joint statement was made today by Dr. Anne Schuchat, Deputy Director of the U.S. Centers for Disease Control and Prevention, and Dr. Peter Marx, Director of the U.S. Food and Drug Administration’s Center for Biology, Evaluation, and Research.

The fact is that in 6 people, after vaccination with “Johnson & Johnson” vaccine, cases of thrombosis were recorded. More than 6.8 million doses of this vaccine have been administered in the United States. Consequently, the chance of developing a thrombus is less than one in a million at this stage. However, in any case, the incident must be carefully studied.

A meeting with the Centers for Disease Control and Prevention is scheduled for Wednesday, and details of this possible, very rare side effect of the vaccine will be announced later. So far it is known that in all six cases we are talking about women in the age group of 18 to 48 years.

One in 6 women died. The second Nebraska State Intensive Care Unit was taken in critical condition, the New York Times reported. In all six cases, events developed 6-13 days after vaccination. Representatives of the company “Johnson & Johnson” have not yet made a statement in this regard.

What has happened in America has already been compared to the events next to the Astrazeneca Covid-19 vaccine in European countries. Several EU countries, the Philippines and the United Kingdom, have already changed the rules for administering the Astrazeneca Covid-19 vaccine.

Both vaccines use similar technology in the cold, inactivated viral vector, doctor Carlos del Rio told CNN today. He is a professor at Emory University and dean of medical school. It is fundamentally different from the vaccine method used by other companies, such as Pfizer-Biontech and Moderna. Astrazeneca and Johnson & Johnson vaccines are similar to Russian Sputnik technology.

“This is a very rare occurrence … when you start administering millions of doses of the vaccine, you only learn about similar events after that. You do not have millions of people in clinical trials,” the professor explained. He immediately congratulated the American health agencies that the investigation of the incident started “very quickly”. “Vaccine safety has always been a priority and I think it is a precise and correct step until we understand what is happening now and how we will act in the future,” said Carlos del Rio.

A new vaccination guide has been introduced in Europe after EU regulators on Wednesday last week spoke of the link between the highly rare and possible fatal thrombosis of the Astrazeneka vaccine. The UK, where the vaccine was jointly developed by the British-Swedish company Astrazeneka and the University of Oxford, said it would offer other alternatives to adults under 30.

The incident is being studied by the Advisory Committee on Immunization Practices at the US Centers for Disease Control and Prevention. Each case is also considered by the Food and Drug Administration. “Until this process is completed, it is advisable to discontinue the vaccine as a precaution. This is important in part because health care organizations are aware of potential side effects and can prepare for appropriate management if treatment of this type of thrombus is needed,” the agencies said in a joint statement. .

.